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It seems fair to say that our understanding of such an incompletely under- 
stood disease as allergic encephalomyelitis is roughly proportional to the degree 
in  which  we  approach  certitude  in  our  attempt  to  produce  the  disease and 
affect its incidence. The  time is past for serf-congratulation on being able to 
produce  the  disease erratically and  with  unpredictable frequencies.  It  seems 
permissible now to ask, as a  next level of our  understanding, that we begin to 
make some finer quantitative distinctions. In what follows we shall confine our 
demmads, and our experiments, to a  single host species, the  mouse, and it will 
be our purpose to report some new operational discriminations in the specifica- 
tions  leading  to  the  production  of  experimental  allergic  encephalomyelitis 
(EAE).I 
The Reference  Point 
Any attempt to refine our discriminations in specifying the things we must do to 
produce EAE must begin with some reference point from which we can measure the 
consequences of manipulation. In the mouse model we have chosen as this reference 
point the 100 per cent incidence level based on histopathologic diagnosis. The mouse 
model uniquely offers us  this choice at the present,  for reasons which will become 
evident below.  In  the  guinea pig, on  the  other hand,  Kies and  Alvord have  con- 
structed a  "disease index" (2) following a similar impulse to devise means permitting 
discriminatory distinctions in  the  production  of  the  disease. Their  employment of 
clinical signs and clinico-chemical data in  the  "disease index" is not practicable in 
* This investigation was supported in part by a research grant, B-1565(C), from the Na- 
tional Institute of Neurological Diseases and Blindness, Public Health Service. A preliminary 
report was published in Fed. Proc., 1961, 20,  (Part 1), 263. 
1  In previous publications we  have  alluded to  this disease  as  "acute  disseminated en- 
cephalomyelitis," or ADE. There is much  to recommend  this terminology, based as it is on 
the pathologic description.  Since  the  publication of the Kies and  Alvord book  "Allergic 
Encephalomyelitis" (1), there has been an increasing trend toward the use of "experimental 
allergic encephalomyelitis," or EAE, as a rubric for the phenomenon. 
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the  instance of  the  mouse  and  we have  used  the  histopathologic diagnosis solely, 
since it has the merit of providing a datum which is indeed the decisive one for render- 
ing a verdict of whether or not the disease has been produced. 
In the mouse the 100 per cent incidence of EAE was achieved (3) by the following 
minimal procedure: The young adult mouse of a  completely susceptible mouse geno- 
type, the BSVS inbred strain, maintained on a nutritionally complete stock diet, was 
"primed" with  an  intraperitoneal injection of Itemophilus  pertussis  vaccine and,  4 
days  later,  was  injected  intracutaneously  with  a  water-in-oil emulsion  of  mouse 
brain proteolipid (Folch and  Lees)  containing mycobacteria as  an  adjuvant.  This 
injection was repeated 10 days later and by 30 days after the first proteolipid injec- 
tion all such  treated mice exhibited the histopathologic signs of EAE. 
The statement that this is the "minimal list" for 100 per cent incidence of mouse 
EAE infers that to do less than this is to fail. This is reasonable enough and easily 
confirmed. What is not so evident, but will be shown  below, is that disturbance of 
other more subtle relationships which lie hidden in this "simple" list, can lead to failure 
too. 
That the "minimal list" might contain hidden complexities came to our attention 
through the publication of Shaw,  Fahlberg, Kies, and Alvord (4)  of their paper on 
suppression  of  EAE  in  guinea  pigs  by  encephalitogenic proteins  extracted  from 
homologous brain. In Fig. 1 of their paper these authors presented without discussion 
or  comment  data  indicating  a  novel  relationship  among  the  operational  entities 
leading to EAE; i.e., production of EAE was affected adversely not only by a reduc- 
tion in the amount of Mycobacterium  tuberculosis as adjuvant, but also by its increase 
beyond a  certain critical level. In a  word, all else being equal, maximal disease as 
estimated by their disease index was achieved only within a  certain range of concen- 
tration of mycobacteria in the injected mixtures, and less disease appeared not only 
with less mycobacteria, but with more. 
Since the precise role of the mycobacteria in adjuvant emulsions is not completely 
understood,  it becomes  important,  on  an  empirical basis at  least,  that  we  define 
this  relationship  more  precisely.  We  present  here  evidence  that  this  paradoxical 
situation apparently has some general basis, for we have now found a  similar set of 
circumstances in the mouse model; and once we admit this we are led to direct our 
attention to quantitative aspects of the other items of the emulsion mixture as well. 
A  multifactorial examination has been made of the consequences  for EAE 
of  varying  in  the  injection  emulsion  (a)  the  mycobacterial species,  (3)  the 
emulsifier and, for a given mycobacterial species, quantitatively varying (c) the 
mycobacteria and (d) the proteolipid antigen. 
Methods and Materials 
The "Minimal" Procedure.--BSVS  mice (5), 2 to 3 months old, on a stock diet of Purina 
fox chow and whole wheat bread and milk ad libitum, were injected intraperitoneally with 
0.5 ml H. pertussis vaccine  (Lederle Laboratories, Pearl River, New York)  (phase  1, equiv- 
alent to 60,000 million/ml, diluted 1:5 with saline). The following day the backs of the animals 
were depilated with an electric shaver and on the 4th day the mice were injected intracu- 
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as an  adjuvant.  1 ml of the control injection mixture was composed of  14 mg lyophilized 
mouse brain proteolipid  (6)  in 0.5  ml 0.85  per  cent saline  containing 0.2  mg merthiolate 
homogenized in a Waring blendor with 2.5 mg dead mycobacteria (H~R,) in 0.5 ml soconol 
(liquid petrolatum,  heavy,  (wsP) distributed  by Socony-Vacuum Oil Co., New York).  The 
0.3 ml dose was divided into 3 blebs through a I inch 21-gauge needle. 10 days later a second, 
similarly  divided  dose  of  proteolipid  emulsion  was  injected.  The  animals  were  examined 
daily for signs of EAE. Many  neurologic signs were noted,  such  as flaccid tail,  difficulty 
righting after a  spin, weakness of legs,  convulsions, circling, but the most reliable sign was 
paralysis of the legs.  On the 20th day after the second proteolipid injection the experiments 
were terminated. Approximately 24 sections obtained from various parts of each brain  were 
stained  with  hematoxylin-eosin  and  the  final  scoring  as  positive  reactors  or  non-reactors 
rested on the histopathologic examination. This procedure has led to EAE in  100 per cent 
of the cases. 
RESULTS 
Role  oJ the  Mycobaaeria~  Species  in  the  Adjutant  Emulsion.--It  had been 
reported to us from two other laboratories  ~, 3 using BSVS mice that there was 
difficulty in producing EAE with proteolipid.  Further examination revealed 
that the adjuvant used in each of these unsuccessful cases was Difco complete 
adjuvant (Difco Laboratories, Detroit,  Michigan). Difco adjuvant was next 
tested in our own laboratory. 20 mice in 2 groups were injected as described 
above with (a) proteolipid +  our adjuvant, and with (b) proteolipid +  Difco. 
In the first group all brains were scored as positive or marked positive. With 
the Difco adjuvant none of the 10 brains showed any lesions. The Difco adju- 
vant contains Mycobacterium  butyricum at a concentration of 0.25  mg per ml. 
This same concentration of M. tuberculosis in the adjuvant emulsion we employ 
is 100 per cent effective. The failure of the Difco adjuvant in these circumstances 
might thus be due to a qualititative difference between these two mycobacterial 
species.  This becomes less certain, however, with the recognition that other, 
and different items of the adjuvant emulsion might be involved, i.e., the emul- 
sifier,* the oil base, the size of the emulsion droplets, etc. 
In order to explore directly the efficacy of different species of mycobacteria 
in EAE production, the following experiment was performed. 
In samples of 10 BSVS mice each the EAE-producing efficacy of a uniform 
dose of proteolipid, 14 mg/ml, was determined when this dose was used, without 
added emulsifier, in conjunction with three different species of mycobacteria: 
tuberculosis, s fortuiturn, 6 and smegmatis, e Five levels of the first, two levels of 
Dr.  George Clark,  Department  of Physiology, University of Buffalo, Buffalo. 
* Dr. Labe C. Scheinberg, Albert Einstein College of Medicine, New York City. 
4 The emulsifier in Difco complete adjuvant is arlacel A  (mannide monooleate). 
5 Kindly  supplied  by  Dr.  H.  D.  Piersma,  Lederle Laboratories  Division,  Pearl  River, 
New York. 
6 Kindly supplied by Dr.  Curtis A. Williams, Jr.,  The Rockefeller Institute,  New York 
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the second, and two levels of the third species were tested as indicated in Table 
I. Even with no acid-fast bacteria in the injection  emulsion 2 of 10 mice were 
positive,  which  agrees  with  the  earlier  findings  of Bell  and  Paterson  (7).  At 
the level of 0.025  mg mycobacteria/ml the production of EAE was increased 
and  tuberculosis,  fortuitum,  and  smegmatis  organisms  were  almost  equally 
effective. With a  10-fold increase in concentration of mycobacteria,  90 to  100 
per cent of the mice showed lesions,  and  again  there  was no great difference 
in the efficacy of the three mycobacteria. The I-I37R~ strain was again  100  per 
cent efficient as an  adjuvant  at  the next  10-fold increase.  It is important  to 
note  that  a  further increase  in concentration resulted  in a  sharp  drop in  the 
production  of  EAE.  The  pattern  of  results  produced  by  M.  tuberculosis  as 
TABLE I 
Effect on the Production of EAE of Varying the Mycobacterial Species Quantitatively and 
Qualitatively in the Antigen*-Adjuvant  Mixture 
Mycobacterla  M. tuberculosis  M. fortuitura  M. smegmatis 
rag~m1 
0 
0.025 
0.25 
2.5 
25.0 
2/i0¢ 
4/9 
10/10 
9/9 
2/9 
3/10 
8/9 
5/10 
lo/lo 
* Proteolipid  antigen  at  14 mg/ml. 
:~ Number positive  EAE/number injected. 
adjuvant  exactly parallels  that  of the  Alvord and  Kies  group  (4)  alluded  to 
earlier. 
Quantitative  Interactions  between  Antigen  and  Adjuvant  Mycobacteria.--The 
demonstration that for a fixed concentration of proteolipid antigen,  14 mg/ml, 
the production of EAE was facilitated  by an increasing  concentration of M. 
tuberculosis, only to be ultimately repressed by an increase beyond an "optimal" 
concentration, suggested a  factorial analysis of the consequences of simultane- 
ously  varying  the  concentrations  of  antigen  and  adjuvant  mycobacteria 
(M. tuberculosis). 
Before the experiment is described a brief comment is necessary on a technical necessity, 
the addition of an emulsifier to the adjuvant mixture. This addition  was necessary because 
upon reduction of the proteolipid concentration from its usual level of 14 mg/ml the adjuvant 
emulsion lost  the stability  provided  by the emulsifying properties  of this  material  and the 
mycobacteria rapidly sedimented on standing. Consequently a commercially available emulsi- 
fier, falba,~ was used for the experiment  described below at a concentration  of 5 per cent, 
replacing part of the oil fraction,  soconol. 
Falba  is an absorption base said to be a mixture  of "oxycholesterine  and cholesterines 
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300 young adult BSVS mice, 150 of each sex, were divided into 30 groups of 10 each, 5 
males and 5 females. These groups were used in a 5 X 6 factorial design with adjuvant myco- 
bacteria ranging in concentration from 0 to 25 mg/ml in five 10-fold increments, and with 
proteolipid ranging from 0.875 mg/ml to 28 mg/ml in 2-fold increments. The 30 mixture 
combinations thus prepared were injected into the mice in the usual manner and the animals 
ultimately scored for EAE similarly. 
The  checker-board  style  of  this  experimental  design  and  the  results  are 
shown  in  Table  II.  It would  be  redundant  to  provide a  statistical  analysis 
here, for the conclusions are easily reached. 
Clearly the quantitative relationships are indeed critical for the production 
of EAE. With 5 per cent falba as an emulsifier only 1  of  30  combinations of 
proteolipid  antigen  and  mycobacteria proved  to  be  100  per  cent  successful. 
(14 mg proteolipid and 2.5  mg H37R,. strain/ml).  In addition  to  confirmation 
TABLE  II 
Effect of 5 Per Cent Falba on the Production of EAE 
M. luberculosis 
mg/r,*t 
0 
0.025 
0.25 
2.5 
25.0 
0.875 
Proteolipid, mg/ml 
0/10" 
O/lO 
O/lO 
O/lO 
1/lO 
* Number positive EAE 
1.75 
O/lO 
O/lO 
O/lO 
0/10 
o11o 
/number injected. 
3.5 
0/10 
O/lO 
O/lO 
6/10 
1/10 
7.0 
o11o 
o/lo 
o11o 
611o 
O/lO 
14.0 
O/lO 
0/lO 
0/10 
10110 
1/10 
28.0 
0/I0 
o/10 
o11o 
519 
4IlO 
of  the  previously observed restriction  of  EAE  production  by too  much  (25 
mg/ml) or too little (0.25 mg/ml and less) mycobacteria, an analogous situation 
was found in the case of the antigen. Thus, with mycobacteria held at the 2.5 
mg/ml level, a  proteolipid concentration  of  14 mg/ml provided EKE  at  100 
per  cent  effectiveness.  But  halving  the  proteolipid  antigen,  or  doubling  it, 
markedly reduced the frequency of EAE. 
Effect of the Emulsifier.--The  results presented in Tables I  and II provided 
a  comparison which now brought into view a previously unanticipated role of 
the  emulsifier in  EAE  production.  Thus,  over a  range  of  concentrations  of 
M. tuberculosis, with proteolipid fixed at 14 mg/ml, but with emulsifier absent, 
a certain broad range of EAE production had been observed, (Table I, column 
1).  Now,  in  Table  II  (considering  the  pertinent  column,  labeled  14  mg 
proteolipid/ml) results were presented following the test of these same concen- 
trations  of  mycobacteria and  antigen,  but  in  the  presence  of  an  emulsifier 
(falba). These two experiences are conveniently compared in Table III. 
It is  evident  that  the  effect of  this  emulsifier  (falba)  is  to  restrict  quite 162  ANTIGEN-ADJ-UVANT  COMPOSITION  IN  EAE 
markedly the range of mycobacteria concentrations which lead to EAE pro- 
duction. 
That this  conclusion had predictive value for other quantitative combina- 
tions  of  antigen  and  mycobacteria became  evident  when  110  BSVS  young 
adult mice in  11 sets of 10 each, as indicated in Table IV, were used to test 
some, though not all,  of the combinations tested in Table II. In the present 
test emulsifier was  omitted.  This omission meant,  of course, a  limitation on 
the  lowest  level  of  proteolipid  antigen  which  would  provide  an  adequate 
emulsification. 
The results are presented in Table IV, which furnishes in the shaded blocks 
the  pertinent  values  obtained  with  falba  for purposes  of  comparison.  The 
TABLE  III 
Effect  on EAE Production  of the Presence  and  Absence  of an Emulsifier  (5 Per Cent)  in the 
Adjuvant Emulsion* 
M, tuberculosis  No emulsifier  With emulsifier (5 per cent falba) 
rag~mr 
0 
0. 025 
0.25 
2.5 
25.0 
2/lo$ 
4/9 
lo/10 
9/9 
2/9 
O/lO 
O/lO 
O/lO 
lo/lo 
1/lO 
* Proteolipid antigen included at  14 mg/ml. 
Number positive EAE/number injected. 
restrictive effects of falba on EAE production are clearly evident over a  con- 
siderable range of antigen-mycobacteria combinations. 
Table IV also presents a  further noteworthy relationship between antigen 
and mycobacteria in the absence of added emulsifier. Starting with 100 per cent 
EAE in the combination 14 mg/ml proteolipid and 2.5 mg/ml M. tuberculosis, 
a diminution of the antigen (1/8) to 1.75 mg/ml reduced EAE to 50 per cent. 
But, with the antigen at this new level, reduction of the mycobacteria to 1/10 
(0.25 mg/ml) enhanced EAE to the 100 per cent level. Contrariwise, increasing 
the mycobacteria 10-fold  (25  mg/ml)  depressed EAE production  to  0.  This 
suggests  that  the critical relationship between antigen and mycobacteria for 
100 per cent EAE rests on a  balance or ratio basis rather than solely on ab- 
solute  amounts.  This  notion  receives  some  further  support  when  another 
inspection is made using the data of Table IV and Table III.  Thus, starting 
again  in  the  absence  of emulsifier at  the  14  mg/ml  proteolipid,  2.5  mg/ml 
mycobacteria level, increasing the mycobacteria 10-fold to 25 mg/ml reduced 
EAE from the 100 per cent  level to 22 per cent (Table III), but at this new JOHANNA  "M', LEE  AND  1KOWARD A.  SCKNEIDER  163 
level  of  mycobacteria, a  subsequent  increase  of  the  antigen  to  28  mg/ml 
restored the EAE to 100 per cent (Table IV). 
Qualitative  Differences  Among  Emulsifiers.--The  experiments  reported 
above demonstrated the restrictive effects of an emulsifier on the production of 
EAE  in  BSVS mice  in  terms  of  certain  critical  quantitative relationships 
between the antigen and mycobacterial components of the adjuvant emulsion. 
Thus far, a single such emulsifier had been examined. That there exist certain 
differences in this regard among the class of emulsifiers which might be used 
was evident when another emulsifier was tested. Aquaphor  ~ was tested at the 
5 per cent level in 20 BSVS mice in 2 anfigen-mycobacteria combinations in 
TABLE  IV 
Production  of  EAE  in  Mice  with  Proteolipid  Emulsions  Containing  No  Added  Emulsifier 
Compared with Emulsions Containing Falba 
M  tuberculosis 
mg/ml 
/ J i ~  / (//// 
o 
No Felba 
•  J/Jl[  b#///, 
/I/JJlJ/1/ 
No Falba 
/111111  2.5  /Folb;'//// 
IIIIIIIIIJ 
No Falba 
///I/ 
25 o  /,Fo,bo///// 
//ll/I/I/IJ 
No Falbo 
1.75 
IIIIII  ,o/Io'////Z 
I1/1/////~ 
4/9 
//////  ,,o/C///2 
IO/10 
¢ IIIlt/ 
IOllO 
5/10 
¢  ]/[[  7d/,o////// 
Itll/////// 
O/I0 
3.5 
I0/10 
Proteolipid, mg/ml 
7.0 
9/10  I0/10' 
14.0  28.0 
f'lll/l  " 
i//I////// 
4/10 
[/////////, 
,o/)9////A 
I0/10 
'11111 
r5/9  ,,,, Y///A 
14/14 
///Hz/1// 
;4110///I/ 
l/l/l/l/l, 
lOll( 
* Number positive EAE/number injected. 
which falba had shown to be restrictive for EAE production; i.e., 7 mg and 
28 mg/ml of proteolipid and 2.5 mg/ml mycobacteria, respectively.  In both 
of these tests EAE was produced 100 per cent and none of the restrictive effects 
exhibited under similar circumstances  by falba were evident. It would appear 
unwise, therefore, to indict all emulsifiers in general for their restrictive proper- 
ties on production of allergic  encephalomyelitis.  Each,  apparently, must be 
considered on its own merits. 
Restriction  of  EAE  Production  Considered Operationally.--The  preceding 
experiments  provide basis enough to show that the operational specifications 
necessary for the 100 per cent production of EAE in a completely susceptible 
genotype must include: (a) the presence or absence of emulsifier; (b) its quaff- 
s Aquaphor is an ointment base composed of derivatives of wool fat mixed with hydro- 
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tative nature,  and  (c)  the  quantitative relations between  proteolipid antigen 
and adjuvant mycobacteria. The consequences of this for studies in EAE are 
obvious  enough,  and  need  not  be  labored  here.  As  part  of  the  operational 
definition of  the  production  of EAE  these  findings stand  on  their own.  The 
question is not long in arising, however, just how it is that these relationships 
discussed above can become so critical as to thwart the attempt to produce the 
disease. In a  word, what goes wrong? 
One simple consideration of these matters springs from a kind of mechanical 
outlook.  For example,  it  will be recalled that  the  EAE-inducing  emulsion is 
TABLE V 
History  of the Injected Intradermal Blebs (0.1 Ml,  3~mouse) of Emulsions  of Varied 
Composition (with 5 Per Cent Falba) 
Emulsion  EAE  Intact Blebs  concentrations 
BSVS 
mice,  No.  1st injection sites  2nd injection sites 
M. tu-  Pr 
ber  cu-  1.°5.. 
mg/ml  mg/ml 
10  ]  . 
10  2.5  7 
10  2.5  14 
10  2.5  28 
10  25  7 
10  25  14 
10  25  28 
Predice( 
day 21 
O/lO: 
6/10 
10/10 
5/10 
O/lO 
1/10 
4/lO 
'ound, 
lay 17 
3/4  30/301 
3/4 
4/4 
3/3 
0/4 
3/4 
2/4 
Day 2 
30/30 
30/30 
30/30 
30/30 
30/30 
30/30 
Day 7 
30/30 
29/30 
26/30 
30/30 
25/30 
24/30 
19/30 
Day lO  Day 17 
30/30  11/12 
25/30  12/12 
20/30  6/12 
29/30  12/12 
10/30  5/12 
14/30  0/12 
14/30  4/12 
Day 2 
18/18 
18/18 
17/18 
18/18 
18/18 
18/18 
18/18 
Day 7 
7/12 
3/12 
5/12 
4/12 
2/12 
1/12 
4/12 
* Number positive EAE/number injected. 
Intact blebs/total number blebs. 
injected intradermally to produce depot blebs which must have some role to 
fulfill in the pathogenesis of the disease. If an added emulsifier, or a change in 
the ratio of antigen and adjuvant mycobacteria, results in a  reduction of the 
frequency of EAE, it is conceivable that  the duration and integrity of these 
depot blebs were thereby altered and we need look no further for an explanation. 
To examine  this possibility 70 BSVS young adult mice were injected, in groups  of 10, 
with seven emulsions, all containing 5 per cent falba emulsifier, but with various ratios of 
antigen proteolipid and adjuvant mycobacteria, as indicated in Table V, with predictable 
departures from,  and including,  the  100 per cent effective  EAE combination.  During the 
usual course of dual injections  the depot blebs of emulsion on the shaved backs of the mice 
were examined daily and on the 10th, 12th, and 17th day the skin sites were excised for his- 
tologic examination from  4,  2, and 4 animals per group,  respectively.  The experiment  was 
terminated on the  17th  day and  brains were removed  for histologic examination. Results 
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The data  presented in  Table V  do not provide any support for a  simple 
mechanical explanation, based on the integrity of the injected blebs. All bleb 
depots were intact for 2 days and more. As Freund (8) showed, an intradermally 
delivered antigen-adjuvant mixture can be excised I day after its establishment 
without  affecting  the  immunologic  consequences;  Freund  and  Lipton  (9) 
showed this  to be directly applicable in EAE in guinea pigs.  In  the present 
instance  it  can  therefore be  inferred  that  the  different dose  mixtures  were 
comparably delivered and  maintained  long  enough  so  that  disparate  conse- 
quences were not to be assigned to disparate beginnings. The ultimate ulceration 
of some of these sites occurred with greater frequency in the instances of the 
higher concentration of M. tuberculosis,  but these events occurred late and were 
not correlated with the restriction of EAE. Apparently, whether a  bleb ulti- 
mately ulcerates  to  the  exterior is  an  event influenced somewhat by myco- 
bacterial concentration, but it may also reflect the technical variation in the 
depth of the intradermal injection. 
The hypersensitivity induced by the first injection is readily apparent from 
the shorter duration to ulceration in the second injection series. 
Histologic examination of the excised skin sites failed to reveal any features 
allowing one to differentiate between events in the skin of a  mouse in which 
EAE was ultimately to appear or in which it was destined not to appear. Figs. 
1 to 4 show, for example, skin sites on the 17th day following the first injection 
of  emulsion.  The  similarity  of  these  two  sections  is  noteworthy  since  the 
mouse in Fig. 1 had EAE as diagnosed by brain  section and the mouse in Fig. 
2 did not. This observed disparity in EAE fulfilled the prediction based on the 
composition of the antigen-adjuvant emulsion. 
DISCUSSION 
Freund's  adjuvant  emulsions,  in  spite  of  their  empiricism,  have  had  an 
increasing use both in animals and man over the last 20 years, and for the best 
of reasons:  they succeed in enhancing immunologic responses both in extent 
and in duration. This is not the place to review the history of Freund's impor- 
tant  discovery and  the phenomenology which has  come to  surround it  (8). 
But since we have been led in this paper to examine certain quantitative rela- 
tions  between  the  antigen  and  mycobacterial  concentrations  the  question 
arises whether the issue has arisen on previous occasions. Freund, in a review 
(10),  directed attention to the importance of oil-and-water ratios,  especially 
when falba was used as an emulsifier. This is noteworthy since we have found 
in  the  present  experiments  that  falba  has  restricting  properties  tending  to 
diminish the chances of immunologic success. But the question of the possible 
critical  quantitative  relations  between  antigen  and  mycobacteria  does  not 
appear to have been systematically attacked before. 
If  our  analysis  pointing  to  the  necessity  of  operational  specification  of 166  ANTIGEN-ADJUVANT  COMPOSITION  IN EAE 
proteolipid  and  mycobacterial  concentrations  in  their  mutual  relations  in 
production of EAE is correct, then certain consequences follow: 
(a)  Failure to produce EAE in susceptible genotype in searches for antigenic 
fractions of brain substance may be due to the possibility that an unsuccessful 
ratio of antigen to mycobacteria was employed, rather than that the material 
was truly non-antigenic. 
(b)  Experiments in which host susceptibility is manipulated must be designed 
to include antigen-mycobacterial ratios over an empirically determined range. 
It is conceivable that a host change may reduce the frequency of EAE in one 
test situation and the same manipulation result in increased frequency of EAE 
in another. In our laboratory we have observed just such puzzling events on 
several occasions. 
(c)  Originally observed in the guinea pig model of EAE (4), and now system- 
atically investigated in the mouse EAE model, the crucial role of the antigen- 
mycobacterial relationship must be considered to be general and not restricted 
to  a  single host  species.  Whether such critical  relations are  to be found in 
other antigen-adjuvant systems as well must be left for further investigation 
to determine. 
(d)  Titration of antigen by dilution in emulsions with fixed mycobacterial 
concentration will,  of course, result in an altered ratio of these components. 
The  reduced  efficacy of the  antigen,  it  must  now be  considered,  may well 
reflect this unbalanced ratio rather than the mere reduction of antigenic mass. 
Indeed,  as  our  experiments  have  now  shown,  the  declining efficacy of  the 
antigen upon dilution can be restored to the full by proportionally reducing the 
mycobacterial  concentration  and  restoring  the  original  ratio.  It  should  be 
remarked  that,  a  priori,  there  must be  some lower  and  finite limit  to  this 
diminution of antigen and mycobacteria in fixed ratio, but in these experiments 
it has not been systematically sought or found. 
Speculation on the basis of the altered EAE frequencies following alteration 
of the antigen-mycobacterial ratios would appear to follow two paths. Either 
we are confronted with aspects of antigen competition or these changing ratios 
result in important changes in the water-oil phase concentrations of the antigen 
The restrictive role of emulsifier, possibly quantitatively affected by the quali- 
tative nature of the emulsifier, would fall into the latter range of speculative 
possibilities. 
SUMMARY 
The production of EAE in the fully susceptible BSVS mouse genotype has 
been found to be dependent on the ratio of proteolipid antigen and adjuvant 
mycobacterial concentration as used in the emulsion of the Freund type. Dis- 
turbance of this ratio, by manipulation of either component, by diminution or 
increase, results in a  decrease in the frequency by which EAE is produced. ~OHANNA  M.  LEE  AND  HOWARD  A.  SCHNEIDER  167 
Simultaneous reduction of antigen and mycobacteria, so that the ratio remains 
unchanged, retains the full EAE-producing power of the emulsion. The limit of 
this has not been ascertained. 
Emulsifying agents have been found to restrict further the permissible limits 
of the anfigen-mycobacterial ratio for full EAE production. Such effects of the 
emulsifier have been found to vary with the qualitative nature of the emulsifier. 
Aquaphor has been found to be less restrictive than falba. 
These phenomena, systematically analyzed here for the mouse, may have an 
application for other antigen-adjuvant systems and for other hosts. 
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EXPLANATION OF PLATES 
PLATE 20 
FIGS.  1  to  4.  Photomicrographs of granulomatous lesions in  the  skin of  BSVS 
mice injected intradermally with an emulsion containing proteolipid, M. tuberculosis, 
and 5 per cent falba. These nodules were excised on day 17 after inoculation. To be 
noted is the insignificant difference  in the extent and character of the lesions. 
FIG. 1.  Nodule of a mouse injected with emulsion containing 14 mg proteolipid/mI 
and 2.5 mg M. tuberculosis/ml. This mouse was scored as EAE-positive. X  103. 
FIG. 2.  Emulsion injected into this mouse contained the same amount of proteo- 
lipid as in that in Fig.  1 but ten times as much M.  tuberculosis  (25  mg/ml). This 
mouse was scored  as EAE-negative. X  103. THE JOURNAL  OF EXPERIMENTAL  MEDICINE  VOL.  115  PLATE  20 
(Lee  and  Schneider:  Antigen-adjuvant composition  in  EAE) PLATE 21 
FIGS.  3  and  4.  These  are  higher  magnifications of  Figs.  1  and  2,  respectively, 
showing the similarity in the type of cellular reaction.  ×  450. THE  JOURNAL OF  EXPERIMENTAL MEDICINE  VOL.  115  PLATE  21 
(Lee and  Schneider:  Antigen-adjuvant  composition  in  EAE) 